Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at the FDA approval of Enflonsia (clesrovimab) and Beyfortus (nirsevimab) as a Monoclonal Antibody Approach for Prevention of RSV Infections in Infants

Ticker(s): MRK, AZN, SNY, PFE, MRNA, GSK

Who's the expert?

Institution: UCLA Medical Center

General Pediatrician in the Division of General Pediatrics at UCLA
Manages 100+ patients per year with RSV

Interview Goal

Discussing the RSV prevention landscape, including vaccines and monoclonal antibodies from Merck and AstraZeneca/Sanofi

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.